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Abstract
It is increasingly evident that human diseases are not isolated from each other. Understanding how different diseases are
related to each other based on the underlying biology could provide new insights into disease etiology, classification, and
shared biological mechanisms. We have taken a computational approach to studying disease relationships through 1)
systematic identification of disease associated genes by literature mining, 2) associating diseases to biological pathways
where disease genes are enriched, and 3) linking diseases together based on shared pathways. We identified 4,195
candidate disease associated genes for 1028 diseases. On average, about 50% of disease associated genes of a disease are
statistically mapped to pathways. We generated a disease network which consists of 591 diseases and 6,931 disease
relationships. We examined properties of this network and provided examples of novel disease relationships which cannot
be readily captured through simple literature search or gene overlap analysis. Our results could potentially provide insights
into the design of novel, pathway-guided therapeutic interventions for diseases.
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Introduction
The combination of genetics and molecular biology has greatly
facilitated the identification of candidate genes for human diseases
[1,2]. More recently, with the completion of human genome
sequencing, genome-wide association, transcriptomic and proteo-
mic expression studies further accelerated the pace of disease gene
hunt [3–6]. It has become evident that very often multiple genes
collectively contribute to the etiology and clinical manifestations of
human diseases including both classic Mendelian diseases and
complex diseases such as T2DM and cancers [7]. Understanding
how different diseases relate to each other will not only provide us
with a global view of human diseasome, but also provide
potentially new insights into the etiology, classification, and design
of novel therapeutic interventions. Network biology has been
proposed as a platform to understand relationships among disease
genes and how they contribute to clinical phenotypes [7,8]. Goh
et. al have taken a step to study relationships among diseases by
constructing a human disease network where two disease are
linked if they share at least one gene based on disease/gene
relationships in the Online Mendelian Inheritance in Man
(OMIM) database [9]. Today, it is well accepted that genes within
a cell do not function alone. They interact with each other to form
complexes or pathways to carry out biological functions [10]. For
some diseases, it has been shown that disease candidate genes are
functionally related in the form of protein complexes or biological
pathways [11]. Thus, defects in different genes lead to similar
clinical phenotypes. Based on this observation, we set out to
investigate disease relationships based on their shared pathways.
First, we took a systematic approach to extract disease associated
genes. Literature mining has been extensively used to generate
relationships between entities (keywords, genes, concepts, diseases,
etc) that co-occur in publications [12–15]. We performed
systematic literature mining to extract genes that are significantly
associated with human disease terms from Medical Subject
Headings (MeSH) in Pubmed abstracts. We then connected
diseases to biological pathways through overlapping genes. Finally
we built a disease network by connecting diseases when they share
common pathways.
Results
We collected 1,028 disease MeSH terms that are associated with
MEDLINE abstracts as Major MeSH Headings and contain at
least 1 disease associated gene (Materials & Methods). On average,
a disease is associated with 12 genes (median=7) and 2,455
publications (median=1,044). In total, 4,195 unique disease
associated genes were identified. With a list of diseases and their
associated genes, we set out to associate diseases to biological
pathways. We mapped 2,167 pathways to 605 diseases and
generated 7,151 significant disease-pathway associations (Materi-
als&Methods). To estimate the background distribution of disease-
pathway association, we randomized the disease genes and
repeated the association process 1000 times (Materials &
Methods). The background distribution follows a normal distri-
bution (mean=104, s.d.=11). Therefore, the observed disease-
pathway associations (7,151) were significantly higher than those
would be observed by chance (P-value,0.001). On average, a
disease is associated with 12 pathways (median=6) and a pathway
is associated with 3 diseases (median=2) (Figure 1a and 1b). For
each disease, the fraction of disease associated genes statistically
mapped to pathways was calculated and its distribution over 605
diseases is shown in figure 1c. On average, 50% of genes from
each disease were statistically associated with pathways (P-
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functionally characterize diseases. Together, these results indicated
that many disease associated genes are related to each other in the
form of biological pathways and are consistent with the modular
view of disease genes [8,11].
Under the assumption that pathways could be used to represent
the underlying biology of disease, we ranked diseases based on the
number of associated pathways. Since many pathways display
redundancy, to certain degree, among themselves, we chose to
rank diseases based on their pathway content index (Materials &
Methods). As shown in table S1, the top 20 list consists of a diverse
array of diseases from 15 MeSH disease categories. On the other
hand, some diseases are connected to only a few pathways and are
therefore likely caused by defects in few specific biological
processes. For example, Myoclonic epilepsies, Turner syndrome,
and Wegener granulomatosis are all mapped to one pathway.
Another way to analyze pathway representation of diseases is to
look at the biological diversity of associated pathways. We
computed the D score (Materials & Methods) to measure the
diversity of the associated pathways for a disease. For example,
nervous system lysosomal storage diseases (D=0) is linked a group
of highly related pathways: cellular monovalent inorganic cation
homeostasis, intracellular pH reduction, lysosomal lumen acidifi-
cation, monovalent inorganic cation homeostasis, PH reduction,
regulation of cellular pH, regulation of intracellular pH, regulation
of pH, all of which are highly related to each other. On the other
hand, some diseases are associated with a diverse array of
pathways. For example, inborn errors metabolism (D=0.94) is
linked to 13 different pathways: aspartate and asparagine
metabolism, benzoate degradation via COA ligation, coenzyme
biosynthetic process, cofactor transport, fatty acid biosynthesis
path 2, glutamate metabolism, mitochondrial transport, regulation
of fatty acid metabolic process, response to corticosteroid stimulus,
response to glucocorticoid stimulus, synthesis and degradation of
ketone bodies, vitamin B7 (biotin) metabolism, and vitamin
transport, consistent with the heterogeneous nature of this
disorder. It is evident that many of the above pathways are
distinct from each other. We also ranked pathways in terms of
their associated diseases (Table S2). The top of the list is mostly
represented by signaling pathways involved in inflammation and
immune response as well as P53 and death receptor signaling
pathways which are involved in many different biological
processes. Note that a pathway can be linked to a set of very
different diseases, indicating the existence of a common biological
mechanism despite of diverse clinical phenotypes. For example,
heterocycle metabolic process (GO BP) is linked to 4 different
diseases: hepatic porphyries, inborn errors purine pyrimidine
metabolism, major depressive disorder, and neural tube defects.
We next built disease relationships based on their associations with
pathways. We reasoned that two diseases are potentially related to
Figure 1. Disease pathway mapping. A) Distribution of the number of mapped pathways per disease. B) Distribution of the number of mapped
diseases per pathway. C) Distribution of the fraction of disease associated genes mapped to pathways.
doi:10.1371/journal.pone.0004346.g001
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We generated a disease network (DN) which consists of 591 nodes
(diseases) and 6,931 edges (disease relationships) based on a default E
score cutoff (Materials & Methods). Among 591 diseases, 587 formed
a giant connected component. DN is a scale-free (data not shown)
and a densely connected network. Average clustering coefficient is
0.61 and on average, any two diseases are 2.8 steps away from each
other. All 22 top MeSH disease categories (C01–C21 and F03) were
represented in DN. About 38% of edges linked diseases sharing the
same MeSH category (versus 19% in random disease networks, P-
value,1e-04). This result suggests that, at the global level, diseases
from the same MeSH category tend to associate with themselves. We
further studied the topology of individual MeSH categories in DN by
calculating within-category distance (WD) (Materials & Methods). A
small WDvalue indicates that diseases for a category lie closer to each
other in DN. Among 22 categories, 13 showed significant WD results
(P-value,0.05). As shown in table S3, diseases from the following
categories lie closer to each other in DN: Parasitic, Immune, Mental,
Virus, Hemic/Lymphatic, Cardiovascular, Environmental, Respira-
tory, Skin/Connective, and Neoplasms. More interestingly, Congen-
ital Hereditary Neonatal and Nervous System are the two categories
where diseases are more separated from each other than would be
expected by chance, indicating that they are diffusely distributed in
the DN and are more likely linked with other categories than with
themselves.
Figure 2 shows a filtered version of DN where 1383 disease
relationships were selected based on a more stringent E score cutoff
(E.4). These relationships covered 367 disease nodes. All but 5
nodes formed a giant connected component (figure 2a) which
displays readily discernable clusters. Two of them were displayed in
detail. One consists of a core of kidney-related diseases plus
hypertension,diabetes,andepilepsy(figure2b).Theother(figure2c)
reveals a central theme of abnormality in lipid metabolism, but also
contains amyloidosis, alzheimer disease, diabetes (type 2), wolff
Parkinson white syndrome, arthritis, and crohn diseases.
Among 6,931 disease relationships, at least 60% of them can be
readily discovered by literature mining: they either share at least
one common publication or gene. The rest of them are potential
candidates for novel disease relationships since they can only be
linked together based on shared pathway(s). Table 1 shows
Figure 2. Disease network. A) A filtered disease network where disease relationships with the E score.4 are displayed. Disease nodes are colored
according to their MeSH disease categories as follows: Neoplasms, red; Congenital_Hereditary_Neonatal, green; Nervous_System, blue;
Cardiovascular, pink; Nutritional_Metabolic, yellow; Female_Urogenital_Pregnancy, aqua; Hemic_Lymphatic, light pink; Musculoskeletal, black;
Digestive, light green; Skin_Connective, olive; all other categories: gray. B) and C) Two examples of disease clusters isolated from the network in A.
doi:10.1371/journal.pone.0004346.g002
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induced dyskinesia and amyotrophic lateral sclerosis are linked
together through FOSB Pathway (BioCarta). In this case, 4 out of
5 genes from FOSB pathway were mapped to the above 2 diseases:
CDK5 and GRIA2 to amyotrophic lateral sclerosis and, FOSB
and PPP1R1B to drug-induced dyskinesia. In another example,
Crohn’s diseases and In-born errors of lipid metabolism are linked
together through the Carnitine transport pathway.
Discussion
We presented here a novel way of discovering relationships
among human diseases based on their associations with biological
pathways. We based our approach on two observations. First, for
many diseases, multiple genes have been identified to collectively
account for clinical phenotypes [7]. Secondly, genes do not
function alone. They coordinate their activities in the form of
complexes or pathways. Therefore, pathways could be used to
represent the underlying biology of diseases. To achieve this goal,
we first identified 4,195 disease associated genes for 1,028 human
diseases through literature mining. For each disease, we identified
pathways where there is a significant enrichment of disease
associated genes. On average, over 50% of associated genes of a
disease are statistically mapped to pathways. This finding re-
enforces the notion that disease genes are related to each other in a
form of functional entity such as pathways or protein complexes
[7,11]. Furthermore, it provides us with an opportunity to
investigate the role of other genes from the same pathway in the
disease development. In majority of cases, the relationship
between diseases and pathways is many-to-many, e.g. a disease
is linked to many different pathways and a pathway is linked to
many different diseases. This observation suggests that a single
pathway can be involved in several different diseases whereas a
disease may have defects in several different biological processes. If
a compound is already available to treat a disease through
modulating the activity of a pathway, then it could potentially be
used to treat other diseases that are tightly associated with the
same pathway. On the other hand, when a disease has defects in
multiple pathways representing distinct biology, a pathway-guided
combination therapy may be employed in the clinic.
We further built a disease network based on disease-pathway
associations. It is a densely connected, small-world, scale-free
network. Overall, diseases from the same MeSH category are more
likely connected to each other. However, at individual category
level, some categories such as Parasitic, Cardiovascular, and Mental
disorders are distributed more densely in the DN, whereas
categories such as Nervous system and Congenital Hereditary
Neonatal are more diffusely distributed. This network could reveal
potentially novel disease relationships that are solely based on
pathway association and cannot be readily identified through
literature search. Currently there are about 40% of disease
relationships in DN that fall into this category. However, given
thestringent criteria used to generate DN,it’s likely that thenumber
of truly novel disease relationship might go lower. Nonetheless,
these novel relationships could offer new insights into disease
etiology, classification, and pathway-based design of novel thera-
peutic opportunities for medicines on the current market.
Materials and Methods
Identification of disease associated genes
We collected 313K names and aliases for human genes. We
collected 1,314 MeSH terms that are related to human diseases, i.e.,
their top MeSH Tree categories fall into C01–C21 and F03. About
Table 1. Examples of novel disease relationships.
Disease 1 Disease 2 Pathway
Drug induced dyskinesia Amyotrophic lateral sclerosis FOSBPATHWAY
Inborn errors lipid metabolism Crohn disease Carnitine transport
Leukemia Ehlers danlos syndrome Role of PBX in fibroblasts signaling pathways
Acute erythroblastic leukemia Hepatic porphyrias AHSPPATHWAY
Tuberous sclerosis Neural tube defects Neural tube closure
Precancerous conditions Listeria infections Immune response MIF in innate immunity response
Crohn disease Neural tube defects Cofactor transport
Hyperhomocysteinemia Von willebrand disease BLOOD CLOTTING CASCADE
Pulmonary hypertension Precancerous conditions Development Endothelin-1/EDNRA signaling
Asthma Ataxia telangiectasia Regulation of DNA recombination
Atherosclerosis Contact dermatitis LDL metabolism during development of fatty streak lesion
Wolff parkinson white syndrome Inborn errors metabolism Regulation of fatty acid metabolic process
Respiratory syncytial virus infections Adenoma Transcription Role of AP-1 in regulation of cellular metabolism
Pulmonary hypertension Endometrial neoplasms Development Endothelin-1/EDNRA signaling
Colitis Inborn errors metabolism Response to glucocorticoid stimulus
Respiratory syncytial virus infections Ataxia telangiectasia Regulation of DNA recombination
Syndactyly Hair diseases Odontogenesis of dentine-containing tooth
Pulmonary eosinophilia Ataxia telangiectasia Regulation of DNA recombination
Glomerulonephritis Pneumocystis pneumonia Regulation of phagocytosis
Hereditary neoplastic syndromes Autoimmune diseases Negative regulation of mononuclear cell proliferation
Column 3 indicates the pathway which has the greatest overall association strength with both diseases.
doi:10.1371/journal.pone.0004346.t001
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were analyzed for co-occurrence of gene names and disease MeSH
terms. The disease MeSH terms must be associated with the
abstracts as Major MeSH Headings. PubMed identifiers corre-
sponding to each disease were retrieved using eUtils (from NCBI);
these were then locally analyzed to map to gene names [16]. For
each disease, the PubMed query ‘‘Disease [majr:noexp]’’ was used.
This restricted the analysis to articles with a disease as a major
MeSH annotation, and ‘‘noexp’’ excluded terms that were
descendants of the disease in the MeSH tree. The reason for the
exclusion was to deemphasize obvious relationships between parent
terms and their children (such as Diabetes Mellitus and Type II
Diabetes Mellitus). Statistical significance of co-occurrence was
assessed using a one-sided Fisher Exact test [15] where a 262
contingency table was constructed for each gene/disease pair with
the following values: c, g-c, d-c, and t, where c denotes the number
of abstracts where a gene name and a disease MeSH term co-occur,
g denotes the number of abstracts where the gene is found, d
denotes the number of abstracts where the disease is found, and t
denotes the total number of abstracts we analyzed. Raw P-values
wereadjusted using false discovery rate(FDR) Benjamini-Hochberg
(BH) procedure [17]. The cutoff of adjusted P-value was set to 0.05.
A total of 4,195 unique genes were associated with 1,028 diseases.
Biological pathways
We collected pathways from BioCarta, GenMAPP, GeneGo,
and Ingenuity. We also included gene sets from Gene Ontology
(GO) Biological process (BP) and Cellular Component (CC) as
pathways in our analysis since these gene sets represent groups of
biologically related genes. For each ontological term in the GO
tree, we included as members any genes that were either
associated with that term or a gene that was associated with an
‘‘is_a’’ descendant of the term. We downloaded BioCarta and
GenMAPP from GSEA MSigDB database v2.5 [18]. Pathways
from GeneGo and Ingenuity were licensed. After excluding
pathways with less than 3 genes or more than 100 genes, we ended
up with 4,323 pathways covering a total of 10,204 unique genes.
Disease-pathway association
Overlap between a disease and a pathway in terms of their
constituent genes was evaluated using a one-sided Fisher Exact
test. Raw P-values were subsequently adjusted using the FDR BH
procedure. Disease-pathway pairs with adjusted P-value,0.05
were collected for further analysis. To estimate the background
distribution of disease-pathway association, we adopted a
randomization-based approach. For each disease, we replaced
each disease associated gene with a randomly selected gene that is
associated with similar number of diseases. Once all diseases were
randomized, they were tested for pathway association. This
process was repeated 1,000 times to generate the background
distribution.
When a disease is associated with several pathways, we
evaluated biological diversity among those pathways based on
their constituent genes by calculating a D score as follows:
D~1{
P
i=j
Pi\Pj
min Pi,Pj ðÞ
nn {1 ðÞ
2
,
Pi,Pj[pathways associated with a disease,
where n denotes the number of pathways associated with a disease,
n(n-1)/2 is the total number of unique pathway pairs, Pi\Pj
denotes number of genes shared by pathways Pi and Pj, and
min Pi,Pj
  
denotes the size of the smaller pathway between Pi
and Pj. A high D score indicates a high degree of gene diversity
among a group of pathways. It equals 1 for a set of non-
overlapping pathways and 0 for completely redundant pathways.
The pathway content index (PCI) was calculated as:
PCI~
P jj
TP ðÞ
UP ðÞ
,
where P denotes a set of pathways associated with a disease, T(P)
denotes the total number of genes from set P, and U(P) denotes the
number of unique genes from set P. When there is no gene
redundancy among associated pathways, the PCI equals the size of
P, and when pathways are completely redundant, PCI equals 1.
When a pathway is associated with several diseases, a similar
measurement, called DCI (disease content index) was calculated in
the similar fashion to capture the diversity of associated diseases.
Network analysis
The largest connected component was first extracted from the
network and used for all subsequent network analysis. Standard
graph-based procedures were used to compute shortest path (SP)
profile and clustering coefficient (CC) for all nodes. Visualization
was done through Cytoscape [19]. When a disease is associated
with multiple MeSH categories, the category that is represented by
most other diseases is chosen for the coloring purpose (figure 2a).
Disease network (DN)
A DN was generated where a node represents a disease and an
edge between two diseases indicates that both share at least one
associated pathway. Note we excluded from DN the disease pairs
where one disease is a descendant of the other in the MeSH tree
since our goal is to capture relationships between different
diseases. We calculated an E score to assess the strength of the
edge (relationship) between two diseases d1 and d2 as follows:
Ed1,d2~{log10tmax
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Pd1,i|Pd2,i
p   
s,
i[pathways associated with both disease d1 and d2,
where Pd1,i, Pd2,i denote P-value for the association between d1
and pathway i, d2 and pathway i, respectively. The default cut-off for
the E score was set to 2log10(0.05) for an edge to be included in
the final network.
The topological distribution of top MeSH disease categories in
the DN was measured by within-category distance (WD). WD for
a given category was calculated as the mean shortest path (SP)
length between all pairs of diseases belonging to that category. We
calculated WD for category c as
WDc~
P
di ,j ðÞ
nn {1 ðÞ
2
, i,j[c
where n denotes the number of diseases from category c in DN and
n(n-1)/2 is the total number of unique disease pairs for c, di ,j ðÞ
denotes the SP distance between disease i and j.
To assess the statistical significance of WD, disease node labels
were randomized and WDs were re-calculated. This process was
repeated 10,000 times. WD results with P-value,0.05 were shown
in table S3.
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Table S1 Top connected diseases. Column 2 indicates the top
MeSH disease categories which a disease belongs to. Multiple
categories are separated by;. Column 3 indicates the number of
disease associated genes for each disease. PCI (Materials&-
Methods) measures the number of distinct pathways associated
with each disease.
Found at: doi:10.1371/journal.pone.0004346.s001 (0.05 MB
DOC)
Table S2 Top connected pathways. Column 3 indicates the
number of disease associated genes for each pathway. DCI
(Materials&Methods) measures the number of distinct diseases
associated with each pathway.
Found at: doi:10.1371/journal.pone.0004346.s002 (0.05 MB
DOC)
Table S3 Within-category (WD) distance of disease categories in
DN. Expected WD was calculated as the average WD of 10000
random disease networks. Categories highlighted in blue are the
ones whose observed WD is significantly higher than expected.
Yellow color indicates the opposite.
Found at: doi:10.1371/journal.pone.0004346.s003 (0.04 MB
DOC)
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